There have been significant therapeutic advances for autoimmune diseases with the development of novel agents targeting inflammatory mediators of the immune system. There are increasing numbers of patients receiving these therapies due to wider access availability, decreased costs and the ability for oral administration with tofacitinib (Xeljanz), which has the novel target mechanism of Janus‐kinase inhibition. Unfortunately, the immunosuppression caused by these agents leads to an increased risk of infection, including mycoses.